| Autor: |
Largay, J., Friedewald, W.T., Elam, M.B., Byington, R.P., Corson, M., Rosenberg, Y., Ginsberg, H.N., Sweeney, M.E., Buse, J.B., Goff, D.C., Jr., Leiter, L.A., ACCORDION Study Investigators, Weiss, D., Lovato, L.C., Lopez, C., Grimm, R., Probstfield, J., O'Connor, P.J., Gerstein, H.C., Fleg, J.L., Ismail-Beigi, F. |
| Jazyk: |
angličtina |
| Rok vydání: |
2017 |
| ISSN: |
0000-0620 |
| DOI: |
10.17615/1qe6-ge30 |
| Popis: |
IMPORTANCE: Patients with type 2 diabetes are at high risk of cardiovascular disease (CVD) in part owing to hypertriglyceridemia and low high-density lipoprotein cholesterol. It is unknown whether adding triglyceride-lowering treatment to statin reduces this risk. OBJECTIVE: To determine whether fenofibrate reduces CVD risk in statin-treated patients with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: Posttrial follow-up of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Study between July 2009 and October 2014; 5 years of follow-up were completed for a total of 9.7 years at general community and academic outpatient research clinics in the United States and Canada. Of the original 5518 ACCORD Lipid Trial participants, 4644 surviving participants were selected based on the presence of type 2 diabetes and either prevalent CVD or CVD risk factors and high-density lipoprotein levels less than 50 mg/dL ( |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
